CSL considers stoppers "more suitable for thimerosal-containing products"
This article was originally published in Scrip
Executive Summary
CSL is investigating the use of alternative stoppers "more suitable to thimerosal-containing products" for use with its multi-dose vials (MDV) of vaccines containing the preservative, in the wake of a recent letter from the US FDA citing GMP concerns. The company told Scrip that it was "working diligently" to address the issues raised by the agency, but noted that it had been "using the MDV stoppers for several years without negative impact".